Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy

The diverse pathways and molecules involved in angiogenesis, the formation of new blood vessels, have been targeted for the treatment of colorectal and other cancers. Vascular endothelial growth factor (VEGF)-A binding to VEGF receptor (VEGFR)-2 is believed to be the key signaling pathway mediating angiogenesis. Other VEGF pathways involved in angiogenesis include VEGF-A, VEGF-B, and placental growth factor binding to VEGFR-1, and VEGF-C and VEGF-D binding to VEGFR-2 and VEGFR-3. VEGF signaling also intersects with other pathways, including angiopoietin/Tie, Notch, hypoxia-inducible factor, and integrin pathways. The roles of these pathways in tumor angiogenesis and in various human cancers will be explored in this article. In addition, preclinical and clinical data on bevacizumab, aflibercept (known as ziv-aflibercept in the US), and investigational antiangiogenic agents in development for the treatment of colorectal and other cancers will be reviewed.

[1]  S. Fox,et al.  VEGF‐B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis , 2001, The Journal of pathology.

[2]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[3]  Jeffrey D. Goldsmith,et al.  Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids , 2003, Current Biology.

[4]  K. Pumiglia,et al.  Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation* , 2001, The Journal of Biological Chemistry.

[5]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[6]  Abhijit Bhat,et al.  Targeting the ANGPT–TIE2 pathway in malignancy , 2010, Nature Reviews Cancer.

[7]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Orci,et al.  Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.

[9]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[10]  Stephen B Fox,et al.  The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression , 2003, The Journal of pathology.

[11]  K. Alitalo,et al.  Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. , 2011, Blood.

[12]  Antonio Duarte,et al.  Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling , 2012, Nature.

[13]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[14]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[16]  G. Neufeld,et al.  The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. , 2002, Advances in experimental medicine and biology.

[17]  Daniel J. Sargent,et al.  Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) , 2012 .

[18]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[19]  L. Ellis,et al.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases , 2000, Cancer.

[20]  L. Schwartz,et al.  Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[21]  M A Konerding,et al.  Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts , 1999, British Journal of Cancer.

[22]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. , 1996, The EMBO journal.

[24]  Liu Feng,et al.  Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma Cells , 2011, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[25]  Yihai Cao.  Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands , 2009, Science Signaling.

[26]  M. Sawyer,et al.  Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. , 2012 .

[27]  Tian-bao Wang,et al.  Serum vascular endothelial growth factor‐C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer , 2011, ANZ journal of surgery.

[28]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[29]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Christian Fischer,et al.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.

[31]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[32]  Tara Karnezis,et al.  VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. , 2012, Cancer cell.

[33]  G. Martiny-Baron,et al.  Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. , 2000, Cancer research.

[34]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[35]  M. Shibuya,et al.  VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells , 1999, Oncogene.

[36]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[37]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[38]  K. Becker,et al.  VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis , 2009, Proceedings of the National Academy of Sciences.

[39]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Gaya,et al.  A preclinical and clinical review of aflibercept for the management of cancer. , 2012, Cancer treatment reviews.

[41]  Dhara N. Amin,et al.  Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities , 2004, Cancer Research.

[42]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[43]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[44]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Harris,et al.  DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. , 2011, Cancer research.

[46]  K. Alitalo,et al.  endothelial growth factor Notch restricts lymphatic vessel sprouting induced by vascular , 2011 .

[47]  Rakesh K. Jain,et al.  Pathology: Cancer cells compress intratumour vessels , 2004, Nature.

[48]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[49]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Greil,et al.  Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Shibuya,et al.  Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.

[53]  P. Pollock,et al.  Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[54]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[55]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  J. Tabernero,et al.  Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. , 2012 .

[57]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[58]  S. Seaman,et al.  Genes that distinguish physiological and pathological angiogenesis. , 2007, Cancer cell.

[59]  M. Sawyer,et al.  Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[61]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[62]  J. Fargnoli,et al.  The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases , 2010, Molecular Cancer Therapeutics.

[63]  D. McDonald,et al.  Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. , 2003, The American journal of pathology.

[64]  Zhiming Zhang,et al.  The expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in the lymphatic metastasis of human breast cancer , 2011 .

[65]  J. Pollard,et al.  VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling , 2011, Nature Cell Biology.

[66]  D. Cheresh,et al.  αV integrins in angiogenesis and cancer. , 2011, Cold Spring Harbor perspectives in medicine.

[67]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[68]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[69]  P. Carmeliet,et al.  Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. , 2005, Human gene therapy.

[70]  S. Rafii,et al.  Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity , 2003, Leukemia.

[71]  K. Nakashiro,et al.  Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. , 2004, Oral oncology.

[72]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[73]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  K. Alitalo,et al.  Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis , 2010, PloS one.

[75]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[77]  Debbie L Hay,et al.  Measurement of Phosphorylated Extracellular Signal–Regulated Kinase 1 and 2 in an Undergraduate Teaching Laboratory with ALPHAscreen Technology , 2009, Science Signaling.

[78]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[79]  S. Oliviero,et al.  Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Martin Büchert,et al.  A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[81]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[82]  Dai Fukumura,et al.  Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre‐Clinical Models , 2010, Microcirculation.

[83]  F. M. Gabhann,et al.  Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer , 2007, British Journal of Cancer.

[84]  M. Shibuya,et al.  Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy , 2011, Proceedings of the National Academy of Sciences.

[85]  S. Fan,et al.  Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. , 2005, Cancer research.

[86]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.